Life science research is shaped by where trials and diagnostics are delivered—and by how organizations manage data, samples, and regulatory evidence. This page maps key market dynamics, from CRO and laboratory services growth to IVD and lab testing demand. We also connect enabling technologies like EDC, LIMS, and ELN to measurable quality and productivity outcomes, while covering lab automation, cloud platforms, and digital pathology.
Key Takeaways
- 10.8% CAGR projected for the global contract research organization (CRO) market from 2024 to 2032, reaching US$281.1 billion by 2032
- 3.6% projected CAGR for the global laboratory services market from 2024 to 2032
- US$333.8 billion value for the global in vitro diagnostics (IVD) market in 2023
- US$3.4 billion global market for lab automation in 2024 (forecast value reported in 2024 industry report)
- 70% of labs reported productivity improvements from adopting LIMS (surveyed result in a 2022 industry benchmarking report)
- 38% reduction in transcription errors with automated ELN workflows vs manual entry reported in a 2021 validation study
- 43% of clinical trials in 2022 used electronic data capture (EDC), a rise from prior years reported by industry analytics
- 72% of life science IT decision-makers plan to deploy cloud data platforms in 2024
- US$15.3 billion value for the global digital pathology market in 2023
- 14.6% of investigational new drugs entered phase 1 and ultimately received FDA approval (median success rate across studies summarized in a 2022 peer-reviewed analysis)
- The average cost to develop and obtain FDA approval for a new drug is about US$2.6 billion (including capitalized R&D costs), per a 2023 updated estimate in a peer-reviewed paper
- Median time from IND submission to NDA approval was 8.8 years in an FDA analysis covering 2006–2015 (median across programs)
- US$1.3 billion global market for clinical trial imaging services in 2023
- US$8.2 billion global market for clinical trial supply services in 2023
- US$4.6 billion global market for biobanking services in 2023
Life science services are scaling fast, led by rapid growth in CRO and labs, digital adoption, and automation gains.
Related reading
01 · Category
Market Size5 stats
01
10.8% CAGR projected for the global contract research organization (CRO) market from 2024 to 2032, reaching US$281.1 billion by 2032
02
3.6% projected CAGR for the global laboratory services market from 2024 to 2032
03
US$333.8 billion value for the global in vitro diagnostics (IVD) market in 2023
04
US$1.7 trillion global government R&D budget in 2022 across OECD countries (latest OECD dataset year referenced in the publication)
05
US$8.0 billion market for preclinical CRO services in 2022
Interpretation
Market Size Interpretation
From a Market Size perspective, life science research demand is expanding on multiple fronts with the global CRO market projected to grow at a 10.8% CAGR to US$281.1 billion by 2032 alongside a larger ecosystem including US$333.8 billion in global IVD market value in 2023 and major public funding with a US$1.7 trillion OECD government R&D budget in 2022.
02 · Category
Productivity & Automation8 stats
01
US$3.4 billion global market for lab automation in 2024 (forecast value reported in 2024 industry report)
02
70% of labs reported productivity improvements from adopting LIMS (surveyed result in a 2022 industry benchmarking report)
03
38% reduction in transcription errors with automated ELN workflows vs manual entry reported in a 2021 validation study
04
Up to 60% faster sample preparation reported for robotic extraction workflows in a peer-reviewed paper benchmarking automated vs manual
05
30% reduction in cycle time for routine ELISA workflows after automation with plate handling robotics in a 2019 implementation study
06
US$1.9 billion global market for laboratory information management systems (LIMS) in 2022
07
FDA-regulated facilities using electronic systems have observed 26% fewer deviations after implementing automated deviation and CAPA workflows (industry evaluation study)
08
Automation can reduce reagent waste by 20%–40% in workflow optimization studies of lab automation (2018–2022 industry synthesis)
Interpretation
Productivity & Automation Interpretation
With lab automation at a US$3.4 billion market in 2024 and LIMS reaching US$1.9 billion in 2022, the productivity case is getting stronger as labs report 70% productivity gains from LIMS adoption alongside up to 60% faster sample preparation and 30% shorter ELISA cycle times when workflows are automated.
03 · Category
Industry Trends5 stats
01
43% of clinical trials in 2022 used electronic data capture (EDC), a rise from prior years reported by industry analytics
02
72% of life science IT decision-makers plan to deploy cloud data platforms in 2024
03
US$15.3 billion value for the global digital pathology market in 2023
04
US$3.9 billion global market for lab information management systems (LIMS) in 2023
05
US$2.7 billion global market for single-cell sequencing technologies in 2023
Interpretation
Industry Trends Interpretation
In 2024 and beyond, life science industry trends are clearly accelerating toward digitized, cloud-enabled research workflows, with 72% of IT decision makers planning cloud data platforms and substantial momentum in data-driven tools like EDC adoption reaching 43% of clinical trials in 2022.
More related reading
04 · Category
Clinical & Validation7 stats
01
14.6% of investigational new drugs entered phase 1 and ultimately received FDA approval (median success rate across studies summarized in a 2022 peer-reviewed analysis)
02
The average cost to develop and obtain FDA approval for a new drug is about US$2.6 billion (including capitalized R&D costs), per a 2023 updated estimate in a peer-reviewed paper
03
Median time from IND submission to NDA approval was 8.8 years in an FDA analysis covering 2006–2015 (median across programs)
04
EMA received 108 applications for centralized marketing authorizations for gene therapy between 2018 and 2023 in the EMA product stats
05
Median duration from first patient in to database lock was 14 months for phase 3 trials in a 2021 peer-reviewed study
06
Randomized controlled trials remain the dominant trial design, representing 63% of clinical trials indexed in ClinicalTrials.gov sampled in a 2022 review
07
Across multiple studies, 50% of published biomedical research findings are estimated to be not reproducible (2016 peer-reviewed review estimate)
Interpretation
Clinical & Validation Interpretation
For the Clinical & Validation category, the path to regulatory validation is long and costly, with median IND to NDA approval taking 8.8 years and an average development and FDA approval cost of about US$2.6 billion, even though only 14.6% of investigational new drugs that enter phase 1 ultimately receive FDA approval.
05 · Category
Cost Analysis8 stats
01
US$1.3 billion global market for clinical trial imaging services in 2023
02
US$8.2 billion global market for clinical trial supply services in 2023
03
US$4.6 billion global market for biobanking services in 2023
04
US$5.1 billion global market for laboratory testing services in 2022
05
FDA’s PDUFA user fee amounts increased to US$3,258,978for a premarket application (type B) for fiscal year 2024 (fee schedule)
06
US$14.1 billion estimated global market for pharmacovigilance services in 2023
07
US$7.8 billion global market for regulatory affairs outsourcing services in 2023
08
US$3.1 billion global market for GMP consulting services in 2023
Interpretation
Cost Analysis Interpretation
The cost pressure in Life Science Research is rising fast across multiple services as the estimated 2023 clinical trial imaging market reaches US$1.3 billion and the pharmacovigilance market climbs to US$14.1 billion, signaling that companies must plan for expanding spend in core cost categories beyond just trial operations.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Kowalski. (2026, February 13). Life Science Research Industry Statistics. Gitnux. https://gitnux.org/life-science-research-industry-statistics
MLA
David Kowalski. "Life Science Research Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/life-science-research-industry-statistics.
Chicago
David Kowalski. 2026. "Life Science Research Industry Statistics." Gitnux. https://gitnux.org/life-science-research-industry-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+15 additional datasets cited (not shown individually)